Indeed, acquired somatic DNA alterations on the gene which encodes EGFR are found in 14–32% of non-small cell lung cancer (NSCLC) cases (Collisson et al., 2014; Zhang et al., 2016) and are correlated with adverse prognosis (Hirsch et al., 2003; Sharma et al., 2007). This evidence concerns the gene EGFR and non-small cell lung carcinoma.